The March Hebrew edition of Forbes magazine had a very large and comprehensive expose
about the biotech and life science industry in Israel. It gives an account of the current
state of the market in general, mentions last years successes and failures and at the
end notes a few companies that they think are worth paying attention to. Matrix Pharma
was one of the companies and following is what they had to say about us:
Matrix Pharma has received patent approval for the development of a drug which prevents
thrombosis from spreading. The drug is in the pre-clinical trial phase and is slated to
reach the final phases within three years. According to the company, annual sales forecasts
for the product are approximately two and a half billion dollars per year.
Matrix Pharma is active in drug research and discovery through the use of computing
systems, applying a method that enables savings in the drug discovery process, improved
quality control, and shortens the time-to-market. Approximately $13 million were invested
by private investors in developing the technology. The Chief Executive Officer of the company
is Sion Balass.
